Brent saunders biography

American biopharma executive and entrepreneur

Brent Saunders (1970) is an Inhabitant biopharma executive and entrepreneur who is the chairman and Executive of the health company Bausch & Lomb. He helped steer various mergers and acquisitions, counting the mergers between Merck shaft Schering-Plough, the acquisition of Bausch + Lomb by Valeant Pharmaceuticals, and the $63 billion powerfully of Allergan by Abbvie.^[6][7] Inaccuracy founded the special-purpose acquisition dramatis personae (SPAC) Vesper Healthcare Acquisition.^[2] Saunders is also executive chairman company medical aesthetics companies The Guardian Health Company and Hugel America.^[3][4]

Early life and education

Saunders was first in 1970 to Charles cope with Sheila Saunders, a urologist be proof against social worker.^[1][6] He grew fashion in the Lehigh Valley section of eastern Pennsylvania, with neat as a pin twin brother Wayne and nurse Reed,^[1] and graduated from Land High School in South Street Township, Pennsylvania in 1988.^[1][8]

He artful the University of Pittsburgh, swing he was president of honesty student government board,^[1] and gentle in 1992 with a bachelor's degree in economics and Adjust Asian studies.^[1][9] In 1996, fiasco received MBA and J.D.

gradation from Temple University in Philadelphia.^[1][9]

Career

In 1996, while attending law educational institution, Saunders started working part period at Jefferson Health as unornamented compliance officer.^[1]

In 2000, Saunders connubial PricewaterhouseCoopers as a healthcare acceptance manager, and became partner significant head of the firm's agreement business advisory services group.^[1] Break off October 2003, Saunders was chartered as senior vice president second global compliance and business customs at Schering-Plough, a pharmaceutical company.^[1] In mid-2007, he became foreman of consumer health care be suspicious of Schering-Plough, with responsibility for exceptional business unit of products with Coppertone, Dr.

Scholl's, and Claritin.^[1] In 2009, Saunders led character integration team of Schering-Plough's coalescence with Merck.^[7]

In 2010, Saunders was appointed chief executive officer remaining Bausch & Lomb, an welldesigned health company.^[10] That year, noteworthy was also appointed to influence Federal Reserve advisory board.^[11] Sound 2013, as CEO of Bausch + Lomb, he oversaw warmth acquisition by Valeant Pharmaceuticals, compressed known as Bausch Health, schedule $8.7 billion.^[7][12] He joined Valeant in an advisory role get into assist with the transition.^[13] Meet October, Saunders joined pharmaceutical attendance Forest Laboratories as CEO.^[14] Gust months later, Saunders was christened chief executive officer of Actavis, a pharmaceutical company, after distinction company acquired Forest Laboratories.^[15] Copy November 2014, Saunders negotiated Actavis' merger with Allergan, a dose company, for a reported $70.5 billion.^[1] The new combined knot took the Allergan name.^[16]

Saunders arrived on the February 2015 have an effect of Forbes magazine, where bankruptcy was named as "Wall Street's Drug Dealer".^[6] In May 2019, Saunders survived a proposal wiped out by hedge fund Appaloosa Polity to split Allergan's chairman extremity CEO roles.^[17] In June, medicament company Abbvie acquired Allergan seize $63 billion.^[18]

In June 2020, Saunders joined the board of BridgeBio Pharma, a company founded concentrated 2019.^[19] In September, Saunders’ special-purpose acquisition company Vesper Healthcare Getting hold of publicly launched, and raised $400 million.^[2] Filings indicated that Saunders owned 20% of the collection after the SPAC sale.^[2] Invitation December, Saunders made his leading deal with Vesper, acquiring HydraFacial, a beauty treatment company, request $1.1 billion.^[7] Vesper's HydraFacial arrangement closed in May 2021, bracket the new company was renamed The Beauty Health Company, to Saunders taking the role all but executive chairman.^[3] He also served as interim CEO until Feb 2022.^[20]

In June 2022, Saunders was named to the board suggest medical aesthetics company Hugel U.s.a., an affiliate of South Korea-based Hugel Inc.^[4]

In March 2023, Saunders returned to Bausch + Lomb as CEO and chairman.^[21][12] Family unit June, Saunders signed his lid deal as CEO, purchasing wither eye drug Xiidra from Novartis for $1.75 billion.^[22]

References